APA (7th ed.) Citation

RSP, S., SS, T., F, H., PL, C., R, R., R, A., . . . A, B. (2022). Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. Clinical pharmacology and therapeutics, 112(1), 101. https://doi.org/10.1002/cpt.2603

Chicago Style (17th ed.) Citation

RSP, Singh, et al. "Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir." Clinical Pharmacology and Therapeutics 112, no. 1 (2022): 101. https://doi.org/10.1002/cpt.2603.

MLA (9th ed.) Citation

RSP, Singh, et al. "Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir." Clinical Pharmacology and Therapeutics, vol. 112, no. 1, 2022, p. 101, https://doi.org/10.1002/cpt.2603.